Aptahem is a biotechnology company focused on developing RNA-based pharmaceuticals, particularly aptamers, for the treatment of acute inflammatory diseases such as sepsis. Aptamers are synthetic nucleic acid polymers that serve as a novel alternative to antibodies, offering advantages such as low immunogenicity and the absence of biological impurities. Aptahem's lead candidate, Apta-1, is currently in early clinical phases targeting sepsis, a condition that poses significant healthcare challenges globally. The company aims to address the urgent medical need for effective treatments for sepsis, which currently lacks efficient therapeutic options.

In addition to its drug development efforts, Aptahem has established a robust intellectual property portfolio, securing patents for its unique RNA aptamer-based drug candidates in key markets, including the US, Europe, and Asia. The company actively collaborates with academic institutions worldwide to explore the multi-mechanistic actions of its candidates across various indications, including inflammation and coagulation. Aptahem's research initiatives are supported by access to advanced laboratory facilities, enabling the company to conduct preclinical studies and enhance its drug development processes. Through these collaborations and research efforts, Aptahem aims to contribute significantly to the understanding and treatment of complex conditions like sepsis.

Sweden

Aptahem AB is a biotechnology company that develops aptamer-based pharmaceuticals for the treatment of life-threatening conditions in which a combination of coagulation and inflammation are involved. The company’s primary pharmaceutical candidate, Apta-1, is being developed with the aim of preventing the high mortality rate caused by organ and tissue damage in patients diagnosed with a septic condition, among others. The company holds patent protection in strategic target markets and actively seeks business development opportunities with potential collaborators.

Aptahem

Company Details